These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 38068521)

  • 1. The Complexity of the Tumor Microenvironment in Hepatocellular Carcinoma and Emerging Therapeutic Developments.
    Argentiero A; Delvecchio A; Fasano R; Andriano A; Caradonna IC; Memeo R; Desantis V
    J Clin Med; 2023 Dec; 12(23):. PubMed ID: 38068521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging Role of Cancer-Associated Fibroblasts in Progression and Treatment of Hepatocellular Carcinoma.
    Akkız H
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma.
    Chen C; Wang Z; Ding Y; Qin Y
    Front Immunol; 2023; 14():1133308. PubMed ID: 36845131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifying cancer-associated fibroblasts as emerging targets for hepatocellular carcinoma.
    Zhang J; Gu C; Song Q; Zhu M; Xu Y; Xiao M; Zheng W
    Cell Biosci; 2020 Oct; 10(1):127. PubMed ID: 33292459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma.
    Wang X; Zhang Q; Zhou J; Xiao Z; Liu J; Deng S; Hong X; Huang W; Cai M; Guo Y; Huang J; Wang Y; Lin L; Zhu K
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36813307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The immunosuppressive tumor microenvironment in hepatocellular carcinoma-current situation and outlook.
    Zhou Z; Hu Y; Wu Y; Qi Q; Wang J; Chen L; Wang F
    Mol Immunol; 2022 Nov; 151():218-230. PubMed ID: 36179604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy.
    Liu Y; Xun Z; Ma K; Liang S; Li X; Zhou S; Sun L; Liu Y; Du Y; Guo X; Cui T; Zhou H; Wang J; Yin D; Song R; Zhang S; Cai W; Meng F; Guo H; Zhang B; Yang D; Bao R; Hu Q; Wang J; Ye Y; Liu L
    J Hepatol; 2023 Apr; 78(4):770-782. PubMed ID: 36708811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment.
    Yang M; Li J; Gu P; Fan X
    Bioact Mater; 2021 Jul; 6(7):1973-1987. PubMed ID: 33426371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour response to hypoxia: understanding the hypoxic tumour microenvironment to improve treatment outcome in solid tumours.
    Bigos KJ; Quiles CG; Lunj S; Smith DJ; Krause M; Troost EG; West CM; Hoskin P; Choudhury A
    Front Oncol; 2024; 14():1331355. PubMed ID: 38352889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exosome-mediated communication in the tumor microenvironment contributes to hepatocellular carcinoma development and progression.
    Wu Q; Zhou L; Lv D; Zhu X; Tang H
    J Hematol Oncol; 2019 May; 12(1):53. PubMed ID: 31142326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
    Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
    Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma.
    Tümen D; Heumann P; Gülow K; Demirci CN; Cosma LS; Müller M; Kandulski A
    Biomedicines; 2022 Dec; 10(12):. PubMed ID: 36551958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deciphering the possible reciprocal loop between hepatic stellate cells and cancer cells in the tumor microenvironment of the liver.
    Ezhilarasan D; Najimi M
    Crit Rev Oncol Hematol; 2023 Feb; 182():103902. PubMed ID: 36621514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor Microenvironment Composition and Related Therapy in Hepatocellular Carcinoma.
    Li Z; Zhang Z; Fang L; Zhao J; Niu Z; Chen H; Cao G
    J Hepatocell Carcinoma; 2023; 10():2083-2099. PubMed ID: 38022729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of the tumour microenvironment in hepatocellular carcinoma by tyrosine kinase inhibitors: from modulation to combination therapy targeting the microenvironment.
    Chen R; Li Q; Xu S; Ye C; Tian T; Jiang Q; Shan J; Ruan J
    Cancer Cell Int; 2022 Feb; 22(1):73. PubMed ID: 35148789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting tumor associated macrophages in hepatocellular carcinoma.
    Xu W; Cheng Y; Guo Y; Yao W; Qian H
    Biochem Pharmacol; 2022 May; 199():114990. PubMed ID: 35288152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CXCL12
    Lu Y; Liu Y; Zuo X; Li G; Wang J; Liu J; Wang X; Wang S; Zhang W; Zhang K; Lei X; Hao Q; Li W; Liu L; Li M; Zhang C; Zhang H; Zhang Y; Gao Y
    J Hepatol; 2024 Oct; ():. PubMed ID: 39393439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor Microenvironment and Nitric Oxide: Concepts and Mechanisms.
    Vedenko A; Panara K; Goldstein G; Ramasamy R; Arora H
    Adv Exp Med Biol; 2020; 1277():143-158. PubMed ID: 33119871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An emerging research: the role of hepatocellular carcinoma-derived exosomal circRNAs in the immune microenvironment.
    Xu HZ; Lin XY; Xu YX; Xue HB; Lin S; Xu TW
    Front Immunol; 2023; 14():1227150. PubMed ID: 37753074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: from bench to bedside.
    Yin Y; Feng W; Chen J; Chen X; Wang G; Wang S; Xu X; Nie Y; Fan D; Wu K; Xia L
    Exp Hematol Oncol; 2024 Aug; 13(1):72. PubMed ID: 39085965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.